FIELD: biotechnology; medicine.
SUBSTANCE: invention relates to biotechnology and medicine. Aptamer specific for the extracellular glycosylated domain of the human CD47 receptor is proposed, which is capable of blocking its interaction with the natural SIRP-alpha ligand.
EFFECT: present invention can find further application in therapy.
1 cl, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| SELECTIVE BIFUNCTIONAL DRUG ON THE BASIS OF FRAGMENTS OF CAMEL SINGLE-CHAIN ANTIBODIES, AIMED ON TUMOR RECEPTORS CD47/CD44, INTENDED FOR THERAPY OF MALIGNANT NEOPLASMS | 2016 |
|
RU2658764C1 |
| METHOD FOR CREATION AND SELECTION OF THE LIBRARY OF MODIFIED APTAMERS | 2016 |
|
RU2652952C1 |
| SELECTIVE BIFUNCTIONAL DRUG ON THE BASIS OF FRAGMENTS OF CAMELIZED SINGLE-CHAIN ANTIBODIES, AIMED TO ONCOTIC RECEPTORS CD47/ERBB2, INTENDED FOR THE THERAPY OF MALIGNANT NEOPLASMS | 2016 |
|
RU2648164C1 |
| MODIFIED 50-LINK DNA-APTAMERS LINKING EXTRACELLULAR DOMAIN EGFR | 2019 |
|
RU2736790C1 |
| MODIFIED DNA-APTAMERS LINKING EXTRACELLULAR DOMAIN EGFR | 2019 |
|
RU2723398C1 |
| APTAMERIC THERAPEUTIC AGENTS APPLICABLE FOR TREATING COMPLEMENT-RELATED DISORDERS | 2006 |
|
RU2406507C2 |
| DNA-APTAMER GR200, RECOGNIZING EXTRACELLULAR DOMAIN OF EGFR | 2019 |
|
RU2729382C1 |
| COMPLEMENT-BINDING APTAMERS AND C5 AGENTS APPLICABLE FOR TREATING OCULAR DISORDERS | 2007 |
|
RU2477137C2 |
| DNA-APTAMER BINDING AN EXTRACELLULAR DOMAIN OF EGFR | 2018 |
|
RU2700097C1 |
| DNA-APTAMER WITH HIGH AFFINITY TO INTERLEUKIN-6 PROTEIN | 2023 |
|
RU2814541C2 |
